329 related articles for article (PubMed ID: 36518162)
21. Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic
Vacas A; Sugden C; Velasco-Rodriguez Ó; Algarabel-Olona M; Peña-Guerrero J; Larrea E; Fernández-Rubio C; Nguewa PA
J Parasitol Res; 2017; 2017():1964531. PubMed ID: 28286673
[No Abstract] [Full Text] [Related]
22. Using Proteomics to Understand How Leishmania Parasites Survive inside the Host and Establish Infection.
Veras PS; Bezerra de Menezes JP
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548150
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum.
Martínez-Flórez A; Martori C; Monteagudo PL; Rodriguez F; Alberola J; Rodríguez-Cortés A
Parasit Vectors; 2020 Jun; 13(1):294. PubMed ID: 32517744
[TBL] [Abstract][Full Text] [Related]
24. Proteomics advances in the study of Leishmania parasites and leishmaniasis.
de Jesus JB; Mesquita-Rodrigues C; Cuervo P
Subcell Biochem; 2014; 74():323-49. PubMed ID: 24264252
[TBL] [Abstract][Full Text] [Related]
25.
Bussotti G; Gouzelou E; Côrtes Boité M; Kherachi I; Harrat Z; Eddaikra N; Mottram JC; Antoniou M; Christodoulou V; Bali A; Guerfali FZ; Laouini D; Mukhtar M; Dumetz F; Dujardin JC; Smirlis D; Lechat P; Pescher P; El Hamouchi A; Lemrani M; Chicharro C; Llanes-Acevedo IP; Botana L; Cruz I; Moreno J; Jeddi F; Aoun K; Bouratbine A; Cupolillo E; Späth GF
mBio; 2018 Nov; 9(6):. PubMed ID: 30401775
[TBL] [Abstract][Full Text] [Related]
26. CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi.
Peng D; Kurup SP; Yao PY; Minning TA; Tarleton RL
mBio; 2014 Dec; 6(1):e02097-14. PubMed ID: 25550322
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.
Martins VT; Machado AS; Humbert MV; Christodoulides M; Coelho EAF
Methods Mol Biol; 2022; 2410():481-502. PubMed ID: 34914064
[TBL] [Abstract][Full Text] [Related]
28. The chemotherapeutic potential of chalcones against leishmaniases: a review.
Tajuddeen N; Isah MB; Suleiman MA; van Heerden FR; Ibrahim MA
Int J Antimicrob Agents; 2018 Mar; 51(3):311-318. PubMed ID: 28668673
[TBL] [Abstract][Full Text] [Related]
29. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
[TBL] [Abstract][Full Text] [Related]
30. The genetic toolbox for Leishmania parasites.
Roberts SC
Bioeng Bugs; 2011; 2(6):320-6. PubMed ID: 22067831
[TBL] [Abstract][Full Text] [Related]
31.
Martínez-López M; Soto M; Iborra S; Sancho D
Front Microbiol; 2018; 9():883. PubMed ID: 29867798
[TBL] [Abstract][Full Text] [Related]
32. From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.
Durieu E; Prina E; Leclercq O; Oumata N; Gaboriaud-Kolar N; Vougogiannopoulou K; Aulner N; Defontaine A; No JH; Ruchaud S; Skaltsounis AL; Galons H; Späth GF; Meijer L; Rachidi N
Antimicrob Agents Chemother; 2016 May; 60(5):2822-33. PubMed ID: 26902771
[TBL] [Abstract][Full Text] [Related]
33. Studies on the antileishmanial properties of the antimicrobial peptides temporin A, B and 1Sa.
Chadbourne FL; Raleigh C; Ali HZ; Denny PW; Cobb SL
J Pept Sci; 2011 Nov; 17(11):751-5. PubMed ID: 21805542
[TBL] [Abstract][Full Text] [Related]
34. Enhancing the copy number of Ldrab6 gene in Leishmania donovani parasites mediates drug resistance through drug-thiol conjugate dependent multidrug resistance protein A (MRPA).
Chauhan IS; Rao GS; Singh N
Acta Trop; 2019 Nov; 199():105158. PubMed ID: 31491399
[TBL] [Abstract][Full Text] [Related]
35. Boosting immunity to treat parasitic infections: Asaia bacteria expressing a protein from Wolbachia determine M1 macrophage activation and killing of Leishmania protozoans.
Varotto-Boccazzi I; Epis S; Arnoldi I; Corbett Y; Gabrieli P; Paroni M; Nodari R; Basilico N; Sacchi L; Gramiccia M; Gradoni L; Tranquillo V; Bandi C
Pharmacol Res; 2020 Nov; 161():105288. PubMed ID: 33160070
[TBL] [Abstract][Full Text] [Related]
36. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
[TBL] [Abstract][Full Text] [Related]
37. Developments in diagnosis and antileishmanial drugs.
Bhargava P; Singh R
Interdiscip Perspect Infect Dis; 2012; 2012():626838. PubMed ID: 23118748
[TBL] [Abstract][Full Text] [Related]
38. State-of-the-art CRISPR/Cas9 Technology for Genome Editing in Trypanosomatids.
Lander N; Chiurillo MA
J Eukaryot Microbiol; 2019 Nov; 66(6):981-991. PubMed ID: 31211904
[TBL] [Abstract][Full Text] [Related]
39. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
[TBL] [Abstract][Full Text] [Related]
40. DNA Topoisomerases of Leishmania Parasites; Druggable Targets for Drug Discovery.
Reguera RM; Elmahallawy EK; García-Estrada C; Carbajo-Andrés R; Balaña-Fouce R
Curr Med Chem; 2019; 26(32):5900-5923. PubMed ID: 29773051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
